The phenotypic and molecular characteristics of antimicrobial resistance of *Salmonella enterica subsp. enterica* serovar Typhimurium in Henan Province, China

Nian Dong¹,²†, Yongrui Li³,⁴†, Jiayong Zhao⁵†, Hui Ma⁶†, Jinyan Wang¹†, Beibei Liang¹, Xinying Du¹, Fuli Wu¹, Shengli Xia⁵, Xiaoxia Yang¹, Hongbo Liu¹, Chaojie Yang¹, Shaofu Qiu¹, Hongbin Song¹, Leili Jia¹†, Yan Li⁴* and Yansong Sun⁷*

Abstract

**Background:** *Salmonella enterica subsp. enterica* serovar Typhimurium infections continue to be a significant public health threat worldwide. The aim of this study was to investigate antibiotic resistance among 147 *S.* Typhimurium isolates collected from patients in Henan, China from 2006 to 2015.

**Methods:** 147 *S.* Typhimurium isolates were collected from March 2006 to November 2015 in Henan Province, China. Antimicrobial susceptibility testing was performed, and the resistant genes of ciprofloxacin, cephalosporins (ceftriaxone and cefoxitin) and azithromycin were detected and sequenced. Clonal relationships were assessed by multilocus sequence typing (MLST) and pulsed-field gel electrophoresis (PFGE).

(Continued on next page)
Results: Of the 147 isolates, 91.1% were multidrug resistant (MDR), with 4.1% being resistant to all antibiotic classes tested. Of concern, 13 MDR isolates were co-resistant to the first-line treatments cephalexin and ciprofloxacin, while three were also resistant to azithromycin. Seven PFGE patterns were identified among the 13 isolates. All of the isolates could be assigned to one of four main groups, with a similarity value of 89%. MLST assigned the 147 isolates into five STs, including two dominant STs (ST19 and ST34). Of the 43 ciprofloxacin-resistant isolates, 39 carried double gyrA mutations (Ser83Phe, Asp87Asn/Tyr/Gly) and a single parC (Ser80Arg) mutation, including 1 isolate with four mutations (gyrA: Ser83Phe, Asp87Gly; parC: Ser80Arg; parE: Ser458Pro). In addition, 12 isolates not only carried mutations in gyrA and parC but also had at least one plasmid-mediated quinolone resistance (PMQR) gene. Among the 32 cephalexin-resistant isolates, the most common extended-spectrum β-lactamase (ESBL) gene was blaoxa-1, followed by blaCTX-M, blaTEM, and blacMY-2. Moreover, the mphA gene was identified in 5 of the 15 azithromycin-resistant isolates. Four MDR isolates contained ESBL and PMQR genes, and one of them also carried mphA in addition.

Conclusion: The high level of antibiotic resistance observed in S. Typhimurium poses a great danger to public health, so continuous surveillance of changes in antibiotic resistance is necessary.

Keywords: S. Typhimurium, Antibiotic resistance, Multidrug-resistant, ESBL, PMQR, Multilocus sequence typing

Background
Salmonella enterica subsp. enterica serovar Typhimurium is an important causative agent of human gastroenteritis and bacteremia in many countries. Worldwide, there are 93.8 million cases of human gastroenteritis due to Salmonella infection annually, associated with a death toll as high as 150,000 [1]. Over 2700 serovars have been identified using the White-Kauffmann-Le Minor scheme [1, 2], of which, S. Typhimurium is the most commonly associated with human and animal disease globally. S. Typhimurium is also the most prevalent serovar causing invasive Nontyphoidal Salmonella infections (iNTS), among iNTS cases, 63.7% occurred in children < 5 years of age globally [3]. Moreover, S. Typhimurium is the second most prevalent serotype in China [4].

Following the emergence of antimicrobial-resistant Salmonella, and in particular, the increasing prevalence of an epidemic multidrug-resistant (MDR) S. Typhimurium strain definitive phage type 104 (DT104) first observed during the 1990s [4], the antimicrobial resistance of Salmonella has become a matter of concern worldwide. Therefore, the appropriate selection of antimicrobial drugs in treating Salmonella infections is necessary. As previously described, cephalexin (CEP) and ciprofloxacin (CIP) are first-line treatment agents for such infections [5], and azithromycin (AZI) has recently been approved by the US Food and Drug Administration as an additional therapy [6]. Salmonella isolates with reduced susceptibility to fluoroquinolones have been frequently reported in several countries, such as Kuwait, the United Arab Emirates, France [7–9]. Moreover, strains resistant to third-generation CEP have been described [10]. Given that these drugs are also first-line treatments for Salmonella infections in children, for whom fluoroquinolones are contraindicated, this represents a troubling development [10, 11].
other clinical symptoms. Fresh fecal specimens collected from diarrhea patients of all ages were inoculated into Carry-Blair medium and forwarded to the regional CDC laboratories within 4 h. The stool samples were enriched in selenite brilliant green broth (Becton Dickinson and Co., Sparks, MD, USA) for 16–18 h at 37 °C, followed by incubation on Salmonella/Shigella agar (Land Bridge, Beijing, China) overnight at 37 °C. The resulting black colonies were streaked onto CHROMagar Salmonella agar (CHROMagar, Paris, France) and kept for 16–18 h at 37 °C to confirm their identity. The resultant purple colonies were then subjected to triple sugar iron agar, motility indole urea agar, L-lysine decarboxylase, and β-galactosidase (o-nitrophenyl-β-D-galactopyranoside) tests. Subsequently, a presumptive Salmonella colony from each sample was stored in semi-solid agar and submitted to our laboratory for further confirmation. Age, gender, geographic origin, date and hospitals were recorded as part of the standard information present on the laboratory request forms. All isolates were identified using API 20E strips (bioMérieux Vitek, Marcy-l’Etoile, France) and tests for O and H antigens by slide aglutination with hyperimmune sera (State Serum Institute, Copenhagen, Denmark). Isolates were assigned to serovars according to the Kauffman-White scheme [7].

**Antimicrobial susceptibility testing**

The susceptibility of each isolate to the following 13 antimicrobial agents was evaluated: ceftriaxone (AXO), cefoxitin (FOX), ampicillin (AMP), amoxicillin/clavulanic acid, 2:1 ratio (AUG2), CIP, nalidixic acid (NAL), AZI, tetracycline (TET), chloramphenicol (CHL), trimethoprim/sulfamethoxazole (SXT), sulfisoxazole (FIS), gentamicin (GEN), and streptomycin (STR). MICs were determined by broth microdilution using a 96-well microtiter plate (SensiTitre CMV3AGNF, Trek Diagnostic Systems; Thermo Fisher Scientific, Inc., West Sussex, UK), with results being interpreted according to the recommendations of the Clinical and Laboratory Standards Institute (CLSI) [16]. Isolates resistant to three or more classes of antimicrobial agents were defined as MDR. The ACSSuT MDR profile, which was the prevalent resistance pattern in S. Typhimurium, was defined as MDR according to the Kauffman-White scheme [7]. Escherichia coli ATCC 25922 was used as a quality control strain, as specified by the Clinical and Laboratory Standards Institute.

**Multilocus sequence typing (MLST)**

MLST analysis of the S. Typhimurium isolates was conducted according to previously described protocols [18]. Seven housekeeping genes (thrA, dnaN, argC, purE, hisD, hemD, and sucA) were amplified by PCR using Ex Taq DNA polymerase (TaKaRa, Dalian, China) and primers whose sequences were downloaded from the abovementioned MLST resource. The PCR cycling conditions were as follows: 95 °C for 5 min; 30 cycles of 95 °C for 30 s, 55 °C for 45 s, and 72 °C for 1 min; and 72 °C for 7 min. The amplicons were sequenced by BGI (BGI, Beijing, China) and the resulting sequence data were checked against the MLST database [19] to establish the sequence types (STs). The eBURST analysis was used with multilocus data to define groups of closely related isolates and display the relatedness between very different multilocus genotypes as previously described [20].

**Pulsed-field gel electrophoresis (PFGE)**

S. Typhimurium isolates co-resistant to CIP and CEP were analyzed by PFGE according to the PulseNet protocol for Salmonella [21]. Salmonella standard strain Braenderup H9812 was employed as the molecular weight marker [22]. Agarose plug slices were digested with XbaI (TaKaRa) at 37 °C for 3 h, and electrophoresis was performed under the following conditions: voltage, 6 V/cm; switch time, 2.16–63.8 s (linear ramping); electric field angle, 120°; electrophoresis time, 19 h; and buffer temperature, 14 °C. PFGE patterns were analyzed using BioNumerics software version 6.0 (Applied Maths, Sint-Martens-Latem, Belgium), employing the Dice correlation coefficient and unweighted pair group method with arithmetic mean, with tolerance set to 1.2%.

**PCR amplification and DNA sequencing**

Quinolone resistance-determining regions of the DNA topoisomerase genes gyrA, gyrB, parC, and parE were amplified by PCR assays as previously described [23]. Presence of the plasmid-mediated quinolone resistance (PMQR) genes aac(6′)-Ib-cr, qnrA, qnrB, qnrD, and qnrS was also established by PCR [24]. Amplification of antibiotic-resistance genes of the blaTEM, blaSHV, blaOXA, and blaCTX-M groups and blaCMV groups were performed by PCR for all isolates resistant to CEP [8, 24, 25]. In addition, for the AZI-resistant isolates, presence of the macroline-resistance genes mphA, mphB, ermA, ermB, ereA, mefA, and msrA were tested [26]. PCR products were fully sequenced by BGI, and all nucleotide sequences were analyzed by comparisons against corresponding sequences in GenBank.

**Statistical analysis**

The chi-squared test and Fisher exact probability test were used for data analysis in SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). P-values < 0.05 were considered to indicate statistical significance.

**Results**

S. Typhimurium isolates from patients in Henan, China, from 2006 to 2015

A total of 147 S. Typhimurium isolates were recovered from 15 hospitals in 11 different geographic regions of...
Henan Province from 2006 to 2015, and the strains were distributed every year in each region (Table S1). Of these, 103 (70.1%) were isolated from patients below 6 years of age, and 91 (61.9%) from those less than 2 years old. Nine (6.1%) isolates were retrieved from patients 7 to 18 years of age, 21 (14.3%) from those 19 to 59 years of age, and 12 (8.1%) from those more than 59 years old. Two isolates (1.4%) derived from individuals of unknown age.

**Antimicrobial susceptibility testing**

The resistance patterns of the 147 S. Typhimurium isolates in response to the 13 antimicrobials tested are shown in Tables 1 and 2. There were 89% of the isolates which were resistant to AMP, TET or FIS, followed by NAL (115, 78.2%), SXT (114, 77.6%), CHL (113, 76.9%), GEN (102, 69.3%), STR (101, 68.7%), and AUG2 (97, 66%). Importantly, some isolates demonstrated strong resistance to at least one of four first-line treatment agents, namely, CIP (43, 29.2%), AXO (24, 16.3%), AZI (15, 10.2%), and FOX (9, 6.1%) (Table 1). All of the antimicrobial resistance levels of S. Typhimurium isolates in Henan were significantly higher than the level described in the 2014 National Antimicrobial Resistance Monitoring System report from the USA [27] (P < 0.05), and the resistance rate of the older generation of antibiotics (AUG2, NAL, CHL, SXT, GEN, STR) remained at a relatively high level, which showed a decline after 2011 (Fig. S1). Meanwhile, the resistance rate of two first-line treatment agents (FOX and AZI) remained at a relatively low level, which showed a rise after 2011. Particularly, the resistance rate of CIP began to decline significantly after 2008 from high (60%) to low (0%), but the resistance rate of AMP and TET remained at a high level (more than 80%) from 2006 to 2015, and the resistance rate of AXO was decreased from 35.7 to 18.2% (Fig. 1). Furthermore, 13 (8.8%) isolates were co-resistant to CIP and CEP, of which, three were also resistant to AZI.

In total, 134 (91.1%) isolates were MDR (Table 2). Of these, 133 (90.5%), 117 (79.6%), 97 (65.9%), and six (4.1%) were resistant to at least four classes of antimicrobials, five classes of antimicrobials, six classes of antimicrobials, and all classes of antimicrobials tested, respectively. Seventy-five (51.0%) MDR isolates exhibited the ACSSuT resistance pattern, of which, 41.3% were co-resistant to CIP, 26.6% were co-resistant to CEP, and 9.3% were co-resistant to AZI. Notably, two (1.4%) ACSSuT-type isolates were co-resistant to all three of these antimicrobials (Table 2). The MDR (≥3 and ≥4 antimicrobial classes) rate remained at a high level, while MDR (≥5 and ≥6 antimicrobial classes) and ACSSuT resistance pattern showed a decline over time.

**Table 1** Antimicrobial susceptibility of 147 S. Typhimurium isolates collected from patients in Henan, China, between 2006 and 2015

| Antimicrobial                  | No. isolates (%) | *NARMS Report n(%) | P-value  |
|--------------------------------|------------------|---------------------|----------|
| **β-Lactams**                  |                  |                     |          |
| Ceftriaxone                    | 24 (16.3)        | 0 (0.0)             | 123 (83.7) | 14 (5.3) | P < 0.05 |
| Cefoxitin                      | 9 (6.1)          | 0 (0.0)             | 138 (93.8) | 14 (5.3) | P < 0.05 |
| Ampicillin                     | 132 (89.8)       | 0 (0.0)             | 15 (10.2)  | 52 (19.8) | P < 0.05 |
| Amoxicillin/clavulanic acid, 2:1 ratio | 97 (66.0)    | 0 (0.0)             | 50 (34.0)  | 14 (5.3)  | P < 0.05 |
| **Quinolones**                 |                  |                     |          |
| Ciprofloxacin                  | 43 (29.2)        | 0 (0.0)             | 104 (70.7) | 1 (0.4)  | P < 0.05 |
| Nalidixic acid                 | 115 (78.2)       | 0 (0.0)             | 32 (21.8)  | 7 (2.7)   | P < 0.05 |
| **Macrolides**                 |                  |                     |          |
| Azithromycin                   | 15 (10.2)        | 0 (0.0)             | 132 (89.8) | 1 (0.4)  | P < 0.05 |
| **Tetracyclines**              |                  |                     |          |
| Tetracycline                   | 132 (89.8)       | 0 (0.0)             | 15 (10.2)  | 59 (22.5) | P < 0.05 |
| **Amphenicols**                |                  |                     |          |
| Chloramphenicol                | 113 (76.9)       | 2 (1.4)             | 32 (21.7)  | 42 (16.0) | P < 0.05 |
| Sulfonamides and synergistic agents |            |                     |          |
| Trimethoprim/sulfamethoxazole  | 114 (77.6)       | 0 (0.0)             | 33 (22.4)  | 6 (2.3)   | P < 0.05 |
| Sulfisoxazole                  | 132 (89.8)       | 0 (0.0)             | 15 (10.2)  | 66 (25.2) | P < 0.05 |
| **Aminoglycosides**            |                  |                     |          |
| Gentamicin                     | 102 (69.3)       | 1 (0.7)             | 44 (30.0)  | 8 (3.1)   | P < 0.05 |
| Streptomycin                   | 101 (68.7)       | 25 (17.0)           | 21 (14.3)  | 65 (42.8) | P < 0.05 |

* The antimicrobial resistant number and rate of 262 S. Typhimurium isolates were cited from the National Antimicrobial Resistance Monitoring System report from the USA in 2014 [27]
Table 2 Multidrug resistance patterns of *S. Typhimurium* isolates collected from patients in Henan, China, between 2006 and 2015

| Multidrug resistance pattern | Number of isolates | Percentage | * NARMS Report (%) | P-value |
|-----------------------------|--------------------|-----------|---------------------|---------|
| ≥ 3 antimicrobial classes    | 134                | 91.1      | 21.8                | P < 0.05 |
| ≥ 4 antimicrobial classes    | 133                | 90.5      | 18.7                | P < 0.05 |
| ≥ 5 antimicrobial classes    | 117                | 79.6      | 15.6                | P < 0.05 |
| ≥ 6 antimicrobial classes    | 97                 | 65.9      | –                   | –       |
| ≥ 7 antimicrobial classes    | 6                  | 4.1       | –                   | –       |
| ACSSuT                       | 75                 | 51.0      | 14.5                | P < 0.05 |
| ACSSuT+AZI                   | 7                  | 4.8       | –                   | –       |
| ACSSuT+CIP                   | 31                 | 21.1      | –                   | –       |
| ACSSuT+CEP                   | 20                 | 13.6      | –                   | –       |
| ACSSuT+CEP+CIP               | 10                 | 6.8       | –                   | –       |
| ACSSuT+CEP+CIP+AZI           | 2                  | 1.4       | –                   | –       |
| Sensitive to all             | 4                  | 2.7       | –                   | –       |

CEP cephalosporins, CIP ciprofloxacin, AZI azithromycin

* The percentage of multidrug resistance patterns of *S. Typhimurium* isolates were cited from the National Antimicrobial Resistance Monitoring System report from the USA in 2014 [27]

(Fig. 2). But the rates of MDR (≥3, ≥4 and ≥ 5 antimicrobial classes) and ACSSuT were significantly higher than the rate described in the 2014 NARMS report [27] (P < 0.05) (Table 2).

MLST and PFGE analyses
MLST assigned the 147 isolates into five STs as follows: ST19 (72, 49.0%), ST34 (67, 45.6%), ST36 (6, 4.0%), ST3265 (1, 0.7%), and ST13(1, 0.7%) (Fig. 3). The eBURST analysis showed there were four eBURST groups between the five STs, ST19 and ST34 belonged to one group, and ST36, ST3265 and ST13 belonged to another groups, respectively. ST19 and ST34 are single locus variants (SLVs) in which one of the seven MLST loci has been altered, due to different sequence values of *dnaN*. PFGE was performed to determine the genetic relatedness of those isolates co-resistant to CIP and CEP. Seven PFGE patterns (Profile 1–Profile 7) were identified among the 13 isolates. All of the isolates could be assigned to one of four main groups (A–D), with a similarity value of 89%. PFGE patterns revealed both diversity and the predominance of certain profiles. Eight isolates belonged to group A, in which three profiles were observed and Profile 3 was the main pattern type including six isolates. Group C and group D contained two isolates each, while only one isolate was present in group B (Fig. 4).

PCR amplification and DNA sequencing
Mechanisms of resistance in the 43 CIP-resistant *S. Typhimurium* isolates were investigated. All of these isolates were found to have gyrA mutation and 39 (90.7%) of them carrying two mutations (Ser83Phe and Asp87Asn/Tyr/Gly), and four (9.3%) carrying only one
(Asp87Asn or Asp87Tyr). Thirty-nine isolates (90.7%) had the parC Ser80Arg mutation. In addition, double gyrA mutations together with a single parC (Ser80Arg) mutation were detected in 38 (88.4%) of the 43 isolates. None carried a gyrB mutation; however, a parE mutation (Ser458Pro) was identified in one isolate, which interestingly also carried two gyrA mutations (Ser83Phe and Asp87Gly) and a single parC (Ser80Arg) mutation. Furthermore, two PMQR determinants were detected: qnrS1 (11 isolates, 25.6%) and aac(6’)-Ib-cr (seven isolates, 16.3%). Among the four isolates with a single gyrA mutation (Asp87Tyr or Asp87Asn), two had the aac(6’)-Ib-cr gene, one had the qnrS gene and one did not have either. None of the isolates carried qnrA, qnrB, or qnrD, and 28 (65.1%) of 43 isolates didn’t carry any PMQR determinants tested.

The 32 S. Typhimurium isolates found to be resistant to CEP antibiotics all carried β-lactamase gene and 16 (50%) had at least two ESBL genes. PCR amplification and sequencing showed that 28 (87.5%) isolates were positive for blaOXA-1, 13 (40.6%) for blaCTX-M, nine (28.1%) for blaTEM-1, and two (6.3%) for blacMY-2. All 32 isolates were negative for blashV. Furthermore, sequencing revealed the presence of blaCTX-M-14, blacTX-M-15, and blacTX-M-55 in six, two, and five isolates, respectively.

PCR showed that only five (33.3%) of the 15 azithromycin-resistant isolates were positive for mphA,
and none of them carried mphB, ermA, ermB, ereA, mefA, or msrA.

Among the 13 isolates resistant to both CIP and CEP, 8 harbored ESBL and carried two mutations in gyrA and one in parC, one harbored ESBL and carried one mutation in parC; 4 harbored ESBL and PMQR genes (Table 3). Moreover, each of these four carried two mutations in gyrA and one in parC. Two isolates each harbored four types of antimicrobial-resistance gene: qnrS/\(\text{aac}(6')-\text{Ib-cr}\)/\(\text{bla}_{\text{CTX-M}}\)/\(\text{bla}_{\text{OXA}}\) (\(n = 1\)) and \(\text{aac}(6')-\text{Ib-cr}/\text{bla}_{\text{OXA}}/\text{bla}_{\text{CTX}}\)/\(\text{mphA}\). One isolate exhibited three antimicrobial-resistance gene types (\(\text{qnrS}/\text{bla}_{\text{CTX}}/\text{bla}_{\text{OXA}}\)), and one other was found to have two types (\(\text{qnrS}/\text{bla}_{\text{OXA}}\)). In addition, 2 of the 13 isolates harbored the \(\text{mphA}\) gene.

### Discussion

*S. Typhimurium* is one of the most prevalent *Salmonella* serotypes in the world, which was frequently resistant to ampicillin, amoxicillin/clavulanic acid, ceftriaxone, chloramphenicol, kanamycin, nalidixic acid, streptomycin, and gentamicin; NAL, nalidixic acid; FIS, sulfisoxazole; AMP, ampicillin; STR, streptomycin; AUG_2, amoxicillin/clavulanic acid, 2:1 ratio; SXT, trimethoprim/sulfamethoxazole. Black indicates “resistant,” grey “intermediate susceptibility,” and white “sensitive.”

### Table 3

| Strain | Years | STs | QRDR mutations | PMQR genes | β-Lactamase genes and types | Macrolide resistance gene |
|--------|-------|-----|----------------|-------------|----------------------------|--------------------------|
| Sall0475 | 2006 | 19  | Ser83Phe, Asp87Asn | Ser80Arg   | – | – | \(\text{bla}_{\text{CTX-M}}\) |
| Sall0485 | 2006 | 19  | Ser83Phe, Asp87Asn | Ser80Arg   | – | – | \(\text{bla}_{\text{CTX-M}}\) |
| Sall0490 | 2007 | 19  | Ser83Phe, Asp87Asn | Ser80Arg   | – | – | \(\text{bla}_{\text{CTX-M}}\) |
| Sall0496 | 2007 | 19  | Ser83Phe, Asp87Asn | Ser80Arg   | – | – | \(\text{bla}_{\text{CTX-M}}\) |
| Sall0507 | 2008 | 19  | Ser83Phe, Asp87Asn | Ser80Arg   | – | – | \(\text{bla}_{\text{CTX-M}}\) |
| Sall0515 | 2008 | 19  | Ser83Phe, Asp87Asn | Ser80Arg   | \(\text{aac}(6')-\text{Ib-cr}\) | – | – | \(\text{bla}_{\text{CTX-M}}\) |
| Sall0525 | 2009 | 19  | Ser83Phe, Asp87Asn | Ser80Arg   | – | – | \(\text{bla}_{\text{CTX-M}}\) |
| Sall0533 | 2010 | 19  | Asp87Tyr          | WT          | – | – | \(\text{bla}_{\text{CTX-M}}\) |
| Sall0544 | 2011 | 19  | Ser83Phe, Asp87Asn | Ser80Arg   | – | – | \(\text{bla}_{\text{CTX-M}}\) |
| Sall0552 | 2012 | 19  | Ser83Phe, Asp87Asn | Ser80Arg   | – | – | \(\text{bla}_{\text{CTX-M}}\) |
| Sall0592 | 2013 | 19  | Ser83Phe, Asp87Asn | Ser80Arg   | – | – | \(\text{bla}_{\text{CTX-M}}\) |

QRDR quinolone resistance-determining region, PMQR plasmid-mediated quinolone resistance, WT wild type
trimethoprim-sulfamethoxazole, and tetracyclines [28–30]. In this study, the S. Typhimurium isolates examined exhibited high rates of resistance to older-generation antimicrobials, and MDR (91.1%) showed the predominant resistance profile over the potential 10 year in Henan province, of which, 51.0% exhibited the ACSSuT resistance pattern. CEP, CIP, and AZI are recommended as first-line treatments for Salmonella infections [5, 6], and surprisingly, resistance rates to these antibiotics among the isolates tested were far higher than the values given in the 2014 National Antimicrobial Resistance Monitoring System (NARMS) report [27]. In addition, we found that the resistance rate of CEP and AZI showed a rise over time, while the resistance rate of CIP began to decline. Of concern, 91.1% of the isolates in the present investigation were MDR, an estimate higher than those in previous studies in Guangdong and Shanghai and in the abovementioned report [27, 31, 32]. More importantly, it is noteworthy that 13 (8.84%) isolates were co-resistant to CIP and CEP, and that all of these were also resistant at least five additional antimicrobial classes, indicating that CIP and CEP resistant S. Typhimurium isolates have been disseminated among communities in Henan. Notably, three of the 13 isolates also exhibited resistance to AZI. Only some clinical S. Typhimurium strains have previously been documented with this resistance profile in China, 12 (2%) of 546 S. Typhimurium isolates resistant to both CIP and AXO were recovered from patients in hospitals during the period of 2005 to 2011; among these 12 isolates, two were also resistant to AZI [13]. And ACS-SuT Salmonella co-resistant to quinolones and cephalosporins will make treatment even more difficult, and the spread of these isolates will pose a real threat to global public health. The above analyses therefore reveal that S. Typhimurium resistance patterns have obviously changed in recent years (Table 2 and Table S1), and empirical therapy should keep pace with these changes. Of concern is 6 (4.1%) strains are resistant to all antibiotic classes tested in our study, it meant we were almost impossible to find an effective treatment for infections. This situation demands regular surveillance of antimicrobial resistance and implements an efficient infection control program. We should control the injudicious use of antibiotics, and manage the antibiotics which are readily available in pharmacies without a prescription. Because antibiotic resistance could be driven by antibiotic consumption, the changing composition of consumption may also reflect alterations in patterns of resistance [33]. Otherwise, antimicrobial resistance will become more and more serious with such a sustained selective pressure. Henan Province is located in Central China, representing approximately 7% of the Chinese population, and is a major transport hub with substantial population mobility. If these MDR strains identified here become as prevalent as definitive phage type 104 worldwide, a more serious threat to national and international public health would be posed. It is therefore essential that antimicrobial resistance be monitored and appropriate drugs be chosen for S. Typhimurium infections.

In order to facilitate understanding of the fundamental factors underlying bacterial antimicrobial resistance and establish measures for its prevention, examination of the molecular mechanisms responsible is urgently needed. Salmonella CIP resistance has principally been attributed to point mutations in the quinolone resistance-determining regions of genes encoding the target gyrase (gyrA and gyrB) and topoisomerase IV (parC and parE) enzymes [7, 34]. Two gyrA mutations affecting amino acid residues 83 and 87 have been identified in S. Typhimurium with high-level resistance to CIP, and variations in other target enzyme-encoding genes such as parC and parE increase such resistance [35, 36]. In the present study, 43 CIP-resistant isolates were identified, all of which had at least one gyrA mutation. Thirty-nine (91%) of these carried two such mutations and showed high-level resistance. One isolate exhibiting a high degree of CIP resistance carried two gyrA mutations (Ser83Phe and Asp87Gly), one parC mutation (Ser80–Arg), and a single parE mutation (Ser458Pro). This parE sequence variation has been reported previously in Taiwan, Hong Kong, and Wuhan [37–39], suggesting that it has the potential to become prevalent in China. As previously described, PMQR genes such as qnr and aac(6’)-Ib-cr have also been established as conferring CIP resistance [40]. The first PMQR gene was identified in a clinical isolate of Klebsiella pneumoniae in 1998 [41], and to date, various PMQR gene types have been detected in clinical Salmonella isolates from humans worldwide [42–44]. In this study, the genes qnrS1 and aac(6’)-Ib-cr were found to be present in 25.6% (11 isolates) and 16.3% (seven isolates) of the 43 CIP-resistant isolates, respectively. Interestingly, 12 isolates simultaneously carried two gyrA mutations, a single parC mutation, and at least one PMQR gene, and thus demonstrated a high level of CIP resistance. However, three isolates highly resistant to CIP harbored only single gyrA mutations affecting amino acid position 87. The fact that they also carried qnrS1 or aac(6’)-Ib-cr indicates that the presence of PMQR genes can increase CIP MICs [37, 40].

Production of β-lactamases is considered the predominant mechanism of bacterial resistance to CEP [45]. Among the 32 CEP-resistant isolates in the current work, blaOXA was the most frequently observed β-lactamase gene (n = 28), with only blaOXA-1 being detected, suggesting that it is prevalent among S. Typhimurium in Henan. OXA-type β-lactamases are characterized by high levels of hydrolytic activity against oxacillin and cloxacillin, and confer resistance to AMP and CEP [46], compounding the difficulty faced in
Choosing antimicrobials for treatment of S. Typhimurium infections. In recent years, the blaOXA gene has also been recorded at high frequencies among other Enterobacteriaceae [47]. Previous studies have shown that CMY-2-type β-lactamas encoded by the plasmid-borne blaCMY-2 gene are the most prevalent and problematic damaging β-lactamase of such enzymes [48]. Although the blaCMY-2 resistance gene has been documented in Salmonella isolates from many countries [49], its presence in China has only been reported in Shandong, Shanxi, and Sichuan Provinces [50–52]. In the current study, one isolate was positive for blaCMY-2, blaCTX-M, and blaOXA and resistant to all antimicrobial classes tested. To the best of our knowledge, this is the first report of blaCMY-2-positive Salmonella in Henan. Of the 32 CEP-resistant isolates in our investigation, 40% harbored blaCTX-M genes, while 28.1% carried the blatem-1 resistance gene. We also found that some of these isolates harbored at least two CEP-resistance genes at the same time. As ESBL genes are usually located on antimicrobial-resistance plasmids, they can be easily transferred between different species of bacteria [53]. We should therefore pay consideration to such phenomena and make every effort to take preventive measures.

ST19 and ST34 have been shown to be common S. Typhimurium STs responsible for infections worldwide [54–56]. Here, these two STs were also the most commonly encountered, indicating their predominance in Henan. Of the 43 CIP-resistant isolates, 39 were categorized as ST19, indicating a relationship between this ST and resistance to CIP (P < 0.05). Moreover, 13 MDR isolates co-resistant to CIP and CEP were identified as ST19, suggesting that the ST19 is prevalent among MDR S. Typhimurium in Henan. According to our data, we note that only by combining etiological and epidemiological information can the characteristics of the spread of resistant clonal strains be better understood.

Conclusions
We analyzed the antimicrobial resistance and basic molecular mechanisms underlying CIP and CEP resistance of S. Typhimurium isolates in Henan, China, and explored their genetic relatedness. These isolates not only exhibited high rates of resistance to traditional antimicrobials but also show high resistance rates to the first-line treatments for Salmonella infection. More importantly, we identified certain MDR isolates co-resistant to CEP, CIP, and AZI, suggesting that the choice of treatment for Salmonella infection has become increasingly difficult. Among the isolates, we detected various plasmid-encoded antimicrobial-resistance genes, including PMQR, ESBL, and mphA genes, with some isolates even carrying two or more types, posing a serious threat to global public health. Therefore, more comprehensive surveillance is essential to prevent further spread of resistant clonal strains.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12879-020-05203-3.

Additional file 1: Figure S1. Trend of resistance rate of 8 uncommon antibiotics in treatment between 2006 and 2015. It was shown in the supplemental material.

Additional file 2. Table S1

Additional file 3. The original Pulsed-field gel electrophoresis (PFGE) images of clinical S. Typhimurium isolates resistant to both ciprofloxacin and cephalosporins. The PFGE profiles of the isolates were distributed in different images, and they were labelled in red below.

Abbreviations
ESBL: Extended-spectrum β-lactamases; PMQR: Plasmid-mediated quinolone resistance; QRDR: Quinolone resistance determining region; MICS: Minimal inhibition concentration; MLST: Multilocus sequence typing; gyrA: DNA gyrase; parC: Topoisomerase IV

Acknowledgements
The authors appreciate the Henan Center for Disease Control and Prevention staff for preparing the isolates.

Authors’ contributions
YS, LJ, SQ, HS and YR conceived the study, ND and YRL wrote the manuscript, JZ and SX and HM participated in the collection of samples, FW, BL, XY, and CY were responsible for sample preservation, JW, ND and YR were responsible for the experiments, YRL and HBL analyzed the data, XD, SQ, HS, YS, LJ and YL provided academic revision for the manuscript. All authors have read and approved the final draft of the manuscript.

Funding
This study was funded by the National Key R&D Program of China (no. 2017YFC1600105 and 2018YFC1603801), the National Science and Technology Major Project (nos. 2018ZX10101003 and 2017YFC1600105) and the National Natural Science Foundation of China (Nos. 81673237 and 81872678). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The data sets generated and analyzed are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The stool samples from human patients with diarrhea were collected and screened in sentinel hospitals based on a national pathogen monitoring system, during our routine surveillance of S. Typhimurium. This study was approved by the ethics committees of the Academy of Military Medical Sciences (Beijing, China). Permission and written informed consent was obtained from patients for sample collection and subsequent usage for research purposes. Written informed consent for participants under 16 was obtained from the parents/guardians of the participants.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Chinese PLA Center for Disease Control and Prevention, 20th Dongdada Street, Beijing 100071, Fengtai District, China. 2Xingcheng Special Service Reception Center of PLA Strategic Support Force, 210th Xinghai South Road, Xingcheng 125100, China. 3Luoyang No.1 Hospital of TCM, 7th Jidu Road, Luoyang 471000, China. 4The Key laboratory of Pharmacology and Molecular Biology, Medical College, Henan University of Science and Technology, 263th Kaiyuan Street, Luolong District, Luoyang 471023, China. 5Institute for Infectious Disease Control and Prevention, Henan Center for Disease Control and Prevention, Zhengzhou, China. 6The Health Bureau of
Logistical Support Department, Central Military Commission of China, 22 Fuxing Road, Beijing 100036, Haidian District, China. 3State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 20 Dongda Street, Beijing 100071, Fengtai District, China.

Received: 26 February 2019 Accepted: 29 June 2020
Published online: 15 July 2020

References

1. Majowicz SE, Musto J, Scallon E, Angulo FJ, Kirk M, O’Brien SJ, Jones TF, Faizl A, Hoekstra RM. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis. 2010;50(6):882–9.

2. Zhang J, Wei L, Kelly P, Freeman M, Jaegersen K, Gong J, Xu B, Pan Z, Xu C, Wang C. Detection of Salmonella spp. using a generic and differential FRET-PCR. PLoS One. 2013;8(10):e76053.

3. Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. Global burden of invasive nontyphoidal Salmonella disease, 2010. Emerg Infect Dis. 2015;21(6):941–9.

4. Ran L, Wu S, Gao Y, Zhang J, Yang C, Liang B, Ma Q, Yi S, Li H, Liu H, Li P, Wu Z, et al. Prevalence and antimicrobial resistance of Salmonella flexneri serotype 2 variant in China. Front Microbiol. 2015;6:435.

5. Glynn MK, Bopp C, Dewitt W, Dabney P, Mokhtar M, Angulo FJ. Emergence of antimicrobial resistance in Salmonella enterica serotype Typhimurium in humans from France (1993 to 2003). J Clin Microbiol. 2006;44(3):700–7.

6. Hakanen A, Kotilainen P, Jalava J, Siltonen A, Huovinen P. Detection of decreased fluoroquinolone susceptibility in Salmonella and validation of nalidixic acid screening test. J Clin Microbiol. 1999;37(11):3572–7.

7. Well FX, Guenser F, Guibert V, Timinouni M, Demartin M, Polomack L, Grimont PA. Multidrug resistance in Salmonella enterica serotype Typhimurium from humans in France (1999). Epidemiology, 20 Dongda Street, Beijing 100071, Fengtai District, China.

8. Weill FX, Guesnier F, Guibert V, Timinouni M, Demartin M, Polomack L, Grimont PA. Multidrug resistance in Salmonella enterica serotype Typhimurium from humans in France (1999). Epidemiology, 20 Dongda Street, Beijing 100071, Fengtai District, China.
39. Cui S, Li J, Sun Z, Hu C, Jin S, Guo Y, Ran L, Ma Y. Ciprofloxacin-resistant Salmonella enterica serotype Typhimurium, China. Emerg Infect Dis. 2008;14(3):493–5.
40. Kim JH, Cho JK, Kim KS. Prevalence and characterization of plasmid-mediated quinolone resistance genes in Salmonella isolated from poultry in Korea. Avian Pathol. 2013;42(3):221–9.
41. Martinez-Martinez L, Patcuau A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet (London, Engl). 1998;351(9105):797–9.
42. Cattoir V, Weill FX, Poirel L, Fabre L, Soussy CJ, Nordmann P. Prevalence of qnr genes in Salmonella in France. J Antimicrob Chemother. 2007;59(4):751–4.
43. Cavaco LM, Hasman H, Xia S, Rarestrup FM, Qin D, a novel gene conferring transferable quinolone resistance in Salmonella enterica serovar Kentucky and Bovismorbificans strains of human origin. Antimicrob Agents Chemother. 2009;53(2):603–8.
44. Cui S, Li J, Sun Z, Hu C, Jin S, Li F, Guo Y, Ran L, Ma Y. Characterization of Salmonella enterica isolates from infants and toddlers in Wuhan, China. J Antimicrob Chemother. 2009;63(1):87–94.
45. Miriagou V, Tassios PT, Legakis NJ, Tzouvelekis LS. Expanded-spectrum cephalosporin resistance in non-typhoid Salmonella. Int J Antimicrob Agents. 2004;23(6):547–55.
46. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39(6):1211–33.
47. Yang C, Li P, Zhang X, Ma Q, Cui X, Li H, Liu H, Wang J, Xie J, Wu F, et al. Molecular characterization and analysis of high-level multidrug-resistance of Shigella flexneri serotype 4s strains from China. Sci Rep. 2016;6:29124.
48. Allen KJ, Poppe C. Occurrence and characterization of resistance to extended-spectrum cephalosporins mediated by beta-lactamase CMY-2 in Salmonella isolated from food-producing animals in Canada. Can J Vet Res. 2002;66(3):137–44.
49. Li XZ, Mehmetra M, Ghimire S, Adewoye L. Beta-lactam resistance and beta-lactamases in bacteria of animal origin. Vet Microbiol. 2007;121(3–4):197–214.
50. Li R, Lai J, Wang Y, Liu S, Li Y, Liu K, Shen J, Wu C. Prevalence and characterization of Salmonella species isolated from pigs, ducks and chickens in Sichuan Province, China. Int J Food Microbiol. 2013;163(1):14–8.
51. Yang B, Qu D, Shen J, Xi M, Zhi S, Cui S, Ji B, Meng J. Antimicrobial susceptibility and related genes of Salmonella serovars from retail food in Shaanxi province. Wei Sheng Wu Xue Bao. 2010;50(6):788–96.
52. Zhang YN, Peng J, Wang Q, Pei ZF, Zhang WJ, Niu ZX. Appearance of blaCMY-2 gene-positive Salmonella isolates of pig origin in China. Int J Antimicrob Agents. 2008;31(3):292–3.
53. Aillet G, Barrett TJ, Butaye P, Cloeckaert A, Mulvey MR, White DG. Salmonella resistant to extended-spectrum cephalosporins: prevalence and epidemiology. Microbes Infect. 2006;8(7):1945–54.
54. Antunes P, Mourao J, Pestana N, Peixe L. Leakage of emerging clinically relevant multidrug-resistant Salmonella clones from pig farms. J Antimicrob Chemother. 2011;66(9):2028–32.
55. Cooke FJ, Brown DJ, Fookes M, Pickard D, Wain J, Roberts M, Kingsley RA, Thomson NR, Dougan G. Characterization of the genomes of a diverse collection of Salmonella enterica serovar Typhimurium definitive phage type 104. J Bacteriol. 2008;190(24):8155–62.
56. Antunes P, Coque TM, Peixe L. Emergence of an IncIgamma plasmid encoding CMY-2 ss-lactamase associated with the international ST19 OXA-30-producing ss-lactamase Salmonella Typhimurium multidrug-resistant clone. J Antimicrob Chemother. 2010;65(10):2097–100.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.